Background and Purpose: Cells die by one of two mechanisms, necrosis or programmed cell death. Necrosis has been implicated in stroke and occurs when the cytoplasmic membrane is compromised. Programmed cell death requires protein synthesis and often involves endonucleolytic cleavage of the cellular DNA. We assessed the potential contribution of programmed cell death to ischemia-induced neuronal death.
Programmed cell death is essential and appropriate in modeling the developing nervous system. In utero, half the neurons that are produced will be terminated, often as a result of the failure to acquire adequate growth factor from the target tissue.5-7 Insufficient exposure to growth factors precipitates PCD, and the degeneration can be blocked by protein and RNA synthesis inhibitors.8-10 Specific growth factors also suppress PCD in cultured primary neurons, where withdrawal of these factors causes cell death by a process that requires macromolecular synthesis. [11] [12] [13] [14] The developmental models clearly demonstrate that neurons have the capacity to initiate PCD. However, the potential role of PCD in neuronal death after a pathophysiological insult is only beginning to be appreciated. 15, 16 We examined the possibility that PCD might be involved in the cell loss resulting from focal cerebral ischemia by taking advantage of the fact that PCD in neurons requires the synthesis of new, as yet unidentified, proteins. Thus, a protein synthesis inhibitor should reduce the size of an infarction resulting from focal ischemia if PCD is involved.
We also looked for the characteristic endonucleolytic degradation of the DNA that is a hallmark of PCD. Two approaches were used. The first approach directly examined DNA extracted from ischemic and nonischemic tissue by gel electrophoresis. The To determine the effect of cycloheximide infusion on the rate of protein synthesis in the rat cortex, six animals were anesthetized with chloral hydrate (500 mg/kg IP) and divided into two groups. A catheter was stereotaxically implanted into the right cerebral ventricle of three rats that were infused with cycloheximide via subcutaneous osmotic pumps as described above. Access holes were drilled through the skull of sham animals (n=3), but catheters were not implanted. An infusion catheter was inserted into the femoral vein of all animals. Ninety minutes after drilling holes through the skull, animals were injected with L-[methyl-'H]-methionine (0.5 mCi, 0.012 ,mol/mL) through the femoral catheter. Forty-five minutes after injection of tracer, animals were killed with an overdose of pentobarbital, and the brain was rapidly removed. The hemicortices were then isolated and divided into three equivalent pieces, frozen on dry ice, and stored at -80°C until processing.
The rate of L-[methyl-'H]-methionine incorporation into protein was measured using a modification of the method described by Xie et al. 21 Tissue samples were weighed and homogenized with a polytron in 2 mL ice-cold water. After removing an aliquot to determine total tritium levels, 2.5 mL of ice-cold 10% trichloroacetic acid (TCA) was added and incubated on ice for 30 minutes. The precipitate was washed twice in 2.5 mL 5% TCA and collected by centrifugation at 900g for 5 minutes. After the second wash, the pellet was redissolved in 0.2% sodium carbonate, 0.1N sodium hydroxide, and an aliquot was combined with 15 mL scintillation cocktail and counted in a liquid scintillation counter.
To examine cellular DNA for endonucleolytic degradation characteristic of PCD, neocortical focal ischemia was produced by the procedure outlined above except that osmotic pumps were not implanted. The brains were removed 24 hours after occlusion, and the ischemic cortex was dissected and immediately frozen on dry ice along with an equivalent size piece of the contralateral cortex. Tissue was minced, and cells were lysed on ice in 5 mmol/L tris(hydroxymethyl)aminomethane (Tris) containing 5 mmol/L ethylenediametetraacetic acid (EDTA) and 0.5% Triton X-100 for 30 minutes. Genomic DNA was pelleted by centrifugation at 13 000g for 20 minutes. DNA that did not sediment during centrifugation was purified by phenol/chloroform/isoamyl alcohol (25:24:1) extraction and ethanol precipitation before RNase A digestion (100 ,ug/mL) for 30 minutes at 37°C. Samples were then reextracted with chloroform/isoamyl alcohol (24:1), reprecipitated in ethanol, and DNA was electrophoresed in 1.8% agarose containing 0.5 ,ug/mL ethidium bromide at 40 mA for approximately 5 hours.
Total DNA was extracted by digesting the cortex in digestion buffer (100 mmol/L NaCl, 10 mmol/L Tris HCl, 25 mmol/L EDTA, 0.5% sodium dodecyl sulfate, 0.1 mg/mL proteinase K) at 50°C for 16 hours. Samples were then processed as described above, including extraction, precipitation, RNase A digestion, reextraction, and precipitation before gel electrophoresis.
Flow cytometry was used to compare DNA within the context of the cell from ischemic and nonischemic tissue. Focal cerebral ischemia was induced as described above, and 24 hours later the animals were anesthetized significant. Data are expressed as mean-+-SD. [mean±SD, n=14] ). Gross behavioral observation did not reveal any obvious differences between the cycloheximide-treated animals and the vehicle controls, and both groups exhibited similar weight loss from the procedure ( Table 2) .
Quantitation of the ischemic zone from the brains of the cycloheximide-treated animals revealed a significant reduction in the size of the infarction when compared with vehicle-treated controls (Table 1, Fig 1) .
The effect of cycloheximide infusion on L-[methyl-3H]-methionine incorporation into TCA-precipitated protein was examined in the cortices of cycloheximide-infused DNA was extracted from the ischemic cortex and the contralateral, nonischemic cortex to determine if DNA degradation had occurred. This experiment permits differentiation between endonucleolytic degradation, as seen by chromatin bands, or lysosomal degradation, which would yield a smear of random-sized DNA. DNA from the nonischemic cortex was largely intact and consequently exhibited little migration in the gel. In contrast, a portion of the DNA from the ischemic zone had undergone endonucleolytic digestion and exhibited the characteristic nucleosome ladder associated with PCD (Fig 2, left and center panels) . The nucleosomal ladder is more difficult to distinguish if fragmented DNA is not initially isolated from genomic DNA in the ischemic cortex (Fig 2, right panel) .
The structural integrity of the DNA was then determined within the context of the cell by flow cytometry. Equivalent-sized pieces of ischemic and nonischemic cortex were obtained from perfusion-fixed animals. Preliminary experiments had indicated that perfusion-fixation was necessary to prevent ischemic damage to normal tissue during dissection and fixation. To obtain a single cell suspension, the samples were rehydrated and isolated from ischemic cortex and the contralateral, nonischemic cortex 24 hours after permanent ipsilateral middle cerebral artery occlusion in three independent preparations and size fractionated using agarose gel electrophoresis. In the left and center panels, fragmented DNA was isolated from genomic DNA before extraction and electrophoresis. The right panel demonstrates the electrophoretic profile after total DNA extraction. Each gel contains a 123-base pair DNA ladder as a size standard. synthesis of those proteins that continue to be translated after ischemia or neurotrophin withdrawal.
Another key consideration in ischemia experimentation is preventing hypothermia. Internal temperature was controlled at 37.5°C during surgery and recovery until the righting reflex was restored and spontaneous motor activity was exhibited (approximately 1.5 
hours).
This precluded any thermal protection during the "therapeutic window" for postischemic hypothermia, which has been determined to be less than 30 minutes.26,27 However, other laboratories have observed reductions in infarct volume when body temperature was reduced to 33°C for 1 hour, starting 1 hour after middle cerebral artery occlusion.28 This raises the possibility that the therapeutic window for hypothermia might be greater than previously thought. Therefore, even though core temperature was controlled for 90 minutes, we cannot categorically exclude a protective contribution from a late-onset hypothermic response to cycloheximide. It should be noted that the protective effect of hypothermia appears to be much more prominent in ischemiareperfusion models. In fact, a recent study comparing reperfusion injury with permanent occlusion observed no statistically significant effect on infarct volume after permanent middle cerebral artery occlusion when body temperature was lowered to 30°C for 2 hours after the occlusion. 29 Obtaining direct evidence for endonucleolytic degradation of DNA from the ischemic cortex provides support for the role of PCD in ischemic cell death in the brain. The 200-base pair bands that correlate with the known size of a mononucleosome are much easier to identify when genomic DNA is first separated from fragmented DNA. It is also apparent from these gels that endonucleolytic degradation appears concurrently with nonspecific DNA 5 The nucleosomal fragments appear before glutamate-induced neuronal death, and inhibiting transcription or endonucleases prevents both DNA degradation and cell death. The extent to which other organs activate a PCD cascade in response to ischemia is not known, but a recent report has identified this phenomenon in kidney, where brief periods of ischemia induce endonuclease activation and the morphological appearance of PCD.34
Our observations on isolated DNA were supported by flow cytometry, which was used to examine the DNA of intact neurons within the context of the cell. Two different patterns of DNA degradation have been described for propidium iodide fluorescence in intact cells that identify PCD (or apoptosis) and distinguish it from necrosis. In whole thymocytes, PCD can be elicited by glucocorticoids. 30 The chromatin condenses in these cells, and a hypodiploid peak of diminished fluorescent intensity is revealed by flow cytometer analysis.35-37This peak is thought to occur because the ability of propidium iodide to intercalate into the DNA is reduced by the chromatin condensation. In contrast, thymocytes undergoing necrotic death show no change in the pattern of DNA fluorescence.
The second pattern of fluorescence can be produced by activating endonucleases in isolated thymocyte nuclei with Ca'+ and Mg2+. In this model, the fluorescent intensity of the nuclei increases in proportion to the extent of DNA degradation.38 In contrast to the intact cells, the chromatin does not condense in these nuclei, and endonuclease digestion of the DNA appears to increase the accessibility of the degraded DNA to the intercalating dye. Thus, when chromatin condensation accompanies endonuclease activity, fluorescent intensity is reduced. In the absence of chromatin condensation, fluorescence intensity increases.
Is chromatin condensation a universal feature of all cells undergoing PCD? Nerve growth factor-deprived superior cervical ganglia neurons undergo PCD that requires macromolecular synthesis.1',14,33 Growth factor removal precipitates extensive neurite degeneration; however, nuclear changes are limited to the appearance of convolutions in the nuclear membrane and a diffuse increase in chromatin density. Interestingly, the late onset of structural changes seen in the nucleus of nerve growth factor-deprived superior cervical ganglia neurons is similar to that described for hippocampal CA1 neurons undergoing delayed neuronal death after transient cerebral ischemic. 22, 39 In both models, nuclear and mitochondrial elements appear intact until frank neuronal degeneration.
Thus, neurons do not exhibit chromatin condensation during cell death caused by ischemia or growth factor deprivation. In turn, one would predict an increase in fluorescent intensity in neurons undergoing PCD due to the increased accessibility of endonuclease-digested DNA to the intercalating propidium iodide dye. While we favor the hypothesis that the increase in fluorescence is due to increased propidium iodide binding, we have not ruled out the remote possibility that ischemic cells are accumulating additional DNA.
The observation that PCDs do not necessarily require apoptosis-like morphology has recently received strong support from the study of two model PCD systems, T cell negative selection and the loss of the intersegmental muscles of the moth Manduca sexta after metamorphosis. 40 These two systems were shown to differ in cellsurface morphology, nuclear ultrastructure, DNA fragmentation, and gene expression during PCD. Therefore, apoptosis-like morphology in hippocampus after transient ischemia does not exclude the possibility that PCD could occur. This is supported by the lack of apoptotic morphology in neurons undergoing PCD after growth factor deprivation.1'
In conclusion, three disparate approaches were used to analyze the mechanisms underlying cell death, and each generated data that are consistent with a role for active PCD after focal cerebral ischemia. These data suggest that novel therapeutic approaches directed at disrupting the process of PCD may be useful for preserving functional neuronal tissue after an ischemic insult. Fascinating "good" and "bad" molecules have been recently discovered to have causally important roles in the apoptotic process. Some genes mediating apoptotic cell death are related to tumor suppressor genes, and their effects oppose those of oncogenes, which promote cell proliferation. In in vivo neuronal death in developing C elegans, genes that regulate neuronal suicide have been cloned. In thymic cells, a specific protein, p53, has been found to be necessary for radiation-induced apoptosis.3 Of importance for its therapeutic potential, a variety of molecular strategies prevent forms of apoptotic cell death. Of possible relevance to stroke, one protein with an "antisuicide" action, Bcl-2, is located in the inner mitochondrial membrane, suggesting that genetically programmed cell death may be inherently tied to metabolic function. 4 Under certain conditions short periods of brain ischemia cause delayed cell death, and neurons, stressed by raised intracellular calcium and the other molecular events that occur in ischemic stroke, make a decision to die. Is that decision executed by activation of a specific gene program, perhaps the same one that causes cell death after raised intracellular calcium in the thymus? If so, it may be prevented by strategies found to prevent apoptosis in other cell types. This important issue for stroke research is opened for scrutiny by the article of Linnik et al. The authors investigated whether there is evidence that a genetic program of cell death may be activated in an animal stroke model. They present evidence for endonuclease activation causing DNA laddering in ischemic brain tissue and show that intraven-
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